+ Watch PMC
on My Watchlist
P/FCF only 6.36 despite 5+ month uptrend which shows no sign of ending soon.
Shares jumped 37% for the week plans to buy Candian firm Paladin labs for $1.6B adjusted earnings 50% higher Rev. came in at $436.8 M ParMerica raised full yr. 2013 to $ 1.71 & 176 per share
Great growth and earnings.
Blues in the Bluegrass for PMC holders recently after two analysts downgrades in August, but believe stock's drop to $7 range offers above average risk/reward from both a technical and fundamental viewpoint. Significant FCF generator; demongraphics favorable for business; insider recently bought over $500,000 in stock - likely enough value here for the shorts to finally cover and look for better pickin's
Generics are the future period. Skyrocketing demand due to boomers and new health care laws. This is a doubler.
Member of the "Penny Stock Posse."
spin-off company from Amerisource Bergen and Kindred Health. ready to run.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions